3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Diffuse Large B-Cell Lymphoma Refractory
1
Interventions
Rituximab
17
Cyclophosphamide
8
zanubrutinib
7
Bendamustine Hydrochloride
7
obinutuzumab
6
Lenalidomide
6
venetoclax
5
blinatumomab
5
acalabrutinib
5
Vincristine
5
fludarabine
4
Prednisone
4
Methotrexate
4
Doxorubicin
4
Cytarabine
4
Brentuximab Vedotin
4
ibrutinib
3
Specimen Handling
3
Dexamethasone
3
Crizotinib
3
tisagenlecleucel
2
tafasitamab
2
polatuzumab vedotin
2
pirtobrutinib
2
pegaspargase
2
idelalisib
2
duvelisib
2
axicabtagene ciloleucel
2
avapritinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
loncastuximab tesirine
×
Lymphoid
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA